{"id":"W2601517348","doi":"10.1200/jco.2012.30.15_suppl.4047","title":"Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET): Results of a planned interim efficacy analysis.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Temsirolimus; Internal medicine; Everolimus; Mucositis; Bevacizumab; Interim analysis; Sunitinib; Clinical endpoint; Oncology; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Leukopenia; Progression-free survival; Adverse effect; Progressive disease; Rash; Surgery; Chemotherapy; Clinical trial; Cancer; PI3K/AKT/mTOR pathway; Discovery and development of mTOR inhibitors","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006992562,0.001565835,0.001451573,0.0005141466,0.0004219824,0.001065493,0.0007565467,0.001656121,0.00333754],"category_scores_gemma":[0.002636961,0.0005984925,0.001404986,0.0003842203,0.0007237218,0.0009905046,0.0004295764,0.002866814,0.0008498391],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008630069,"about_ca_system_score_gemma":0.001442217,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004182854,"about_ca_topic_score_gemma":0.0009218077,"domain_scores_codex":[0.9980003,0.001474136,0.00007781748,0.0001632875,0.00009943084,0.0001849287],"domain_scores_gemma":[0.9980024,0.000563244,0.000394755,0.0001378547,0.0001125273,0.0007892894],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9141356,0.02204773,0.005699812,0.0002658413,0.001335653,0.000178113,0.0001413763,0.001823496,0.01133154,0.0002142119,0.002887496,0.03993921],"study_design_scores_gemma":[0.6539335,0.3273241,0.01076313,0.00003404246,0.0006751456,0.0002258396,0.00003190916,0.001733126,0.00250988,0.0002467794,0.00249933,0.00002318956],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9819673,0.003687105,0.001947841,0.0009812702,0.0002269704,0.005580623,0.002533657,0.0001393759,0.002935896],"genre_scores_gemma":[0.9755633,0.001280535,0.005191376,0.001249752,0.0002495001,0.00725457,0.005615363,0.00005271343,0.003542821],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006992562,"threshold_uncertainty_score":0.03698063,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1189870199043359,"score_gpt":0.4999713452551495,"score_spread":0.3809843253508136,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}